FDA Regulatory Integrity and the Mechanics of Pharmaceutical Market Entry The relationship between pharmaceutical manufacturers and the Food and Drug […]
Can Drug Companies Bribe the FDA? Unveiling the Truth Behind Pharmaceutical Influence Read Post »
For pharma IP teams, portfolio managers, R&D leads, and institutional investors who need to read case trajectories — not just
Predicting Drug Patent Litigation Outcomes Read Post »
I. Executive Summary Pharmaceutical patents are not legal formalities. They are the single most important determinant of whether a drug
Drug Patent Lifecycle: The Complete Pharma IP Strategy Playbook Read Post »
The pharmaceutical landscape is a dynamic realm, continually evolving with groundbreaking discoveries and innovative therapies. At the heart of this
5 Ways Pharmacists Can Improve Clinical Trials Read Post »
The blueprint for drug competition is clean on paper. A company wins a 20-year patent, recovers its R&D investment during
Off-Patent, Zero Competition: Why Some Off-Patent Drugs Have No Generic Rivals Read Post »
I. Executive Summary The pharmaceutical industry operates within a high-stakes environment where innovation, intellectual property protection, and market dynamics are
Using Patent Filings to Model Branded Pharmaceutical Post-Expiration Strategies Read Post »
1. Why the NCE-Only Mental Model Is Costing You IP Value Key Takeaways The phrase ‘patent cliff’ has been overused
Why Effective Patent Life Is the Only Number That Matters Every pharmaceutical deal, licensing negotiation, and portfolio valuation ultimately hinges
1. Why API Supplier Selection Is an IP and Valuation Decision, Not a Procurement Function Most pharmaceutical procurement teams still
Get fresh news and insights, drug patent expirations & more…
